Welcome to our dedicated page for ICU MEDICAL INC/DE SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ICU MEDICAL INC/DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ICU MEDICAL INC/DE's regulatory disclosures and financial reporting.
ICU Medical, Inc. (ICUI) filed a Form 8-K to report that it furnished a press release announcing its financial results for the third quarter of 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition). The filing lists ICU Medical’s common stock on the Nasdaq Global Select Market under the symbol ICUI. This 8-K serves to make the company’s Q3 2025 results announcement available to the market via the furnished exhibit.
Vivek Jain, Chairman and CEO of ICU Medical, reported a Form 4 disclosing transactions dated 09/12/2025. The filing shows a gift of 63,641 shares of common stock to two trusts established for family members who share the same household; the reporting person disclaims beneficial ownership of the shares held by those trusts. After the reported transactions, Mr. Jain retained 66,508 shares directly and the trusts hold 152,339 shares indirectly. The form was signed by an attorney-in-fact on 09/15/2025.
David C. Greenberg, a director of ICU Medical, Inc. (ICUI), reported open-market purchases on 08/27/2025. The Form 4 shows two non-derivative purchases: 602 shares at a weighted-average price of $126.1428, bringing his direct beneficial ownership to 7,362 shares, and 598 shares at a weighted-average price of $126.6895, bringing his direct beneficial ownership to 7,960 shares. The filing also discloses 500 shares held indirectly by a trust. The purchases were executed in multiple transactions within the disclosed price ranges; the filer offers to provide detailed per-transaction pricing on request.
Vivek Jain, Chairman and CEO of ICU Medical, Inc. (ICUI), reported purchases of company common stock on 08/14/2025. He acquired 2,378 shares at a weighted-average price of $112.1165 (purchases ranged $111.75–$112.435) and 19,551 shares at a weighted-average price of $112.9232 (purchases ranged $112.48–$113.435). Following these transactions, Mr. Jain beneficially owns 130,149 shares directly and 88,698 shares indirectly through a trust; a prior direct holding of 110,598 shares is shown prior to the second reported purchase line. The Form 4 was signed by an attorney-in-fact, Paula Darbyshire.
Janus Henderson Group plc and an affiliated fund reported beneficial ownership stakes in ICU Medical, Inc. Janus Henderson Group plc is shown with shared voting and dispositive power over 2,470,146 common shares, equal to 10.0% of the class. Janus Henderson Enterprise Fund reports shared voting and dispositive power over 1,230,753 shares, equal to 5.0% of the class. The filing also notes that JHIUS may be deemed beneficial owner of 2,411,637 shares ( 9.8% ) with shared voting and dispositive authority.
The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. Power of attorney and signature attestations are included, identifying the compliance officer who signed on behalf of the reporting entities.
ICU Medical registered 2,150,000 shares of its common stock for issuance under the Third Amendment to its Amended and Restated 2011 Stock Incentive Plan, approved by stockholders at the 2025 annual meeting on May 13, 2025. The filing confirms these additional shares are the same class as prior awards and incorporates earlier Form S-8 and 10-K registrations by reference, and includes related exhibits and legal opinions.